Abstract: An online concierge system allows users to order items within discrete time intervals later than a time when an order was received. Each order may require a different set of characteristics for fulfilment by shoppers. Because different shoppers may have different capabilities, it is most efficient to reserve shoppers with specialized characteristics for orders that require them. The online concierge system maintains a set of hierarchical structures for different characteristics of shoppers, with each level in a hierarchical structure having a value. To select a shopper to fulfill an order, the online concierge system scores identifies groups of shoppers having characteristics capable of fulfilling the order based on levels in the hierarchical structure for each characteristic of a group. A shopper from a group having a minimum score is selected to fulfill the order.

Abstract: A method is applied to a system including a host cluster and at least one pair of storage arrays. The host cluster includes a quorum host, which includes a quorum unit. The quorum host is an application host having a quorum function. A pair of storage arrays includes a first storage array and a second storage array. The quorum host receives a quorum request, temporarily stops delivering a service to the first storage array and the second storage array, determines, from the first storage array and the second storage array, which is a quorum winning storage array and which is a quorum losing storage array according to logic judgment, stops the service with the quorum losing storage array, sends quorum winning information to the quorum winning storage array, and resumes the delivered service between the host cluster and the quorum winning storage array.

Abstract: A joint link-level and network-level intelligent system and method for dynamic spectrum anti-jamming are provided. The system includes a link-level anti-jamming subsystem and a network-level anti-jamming subsystem. The link-level anti-jamming subsystem sets a reward value as system transmission throughput in a single decision cycle, and a user makes an intelligent frequency usage decision based on the obtained reward value to skip a frequency band in which jamming exists. The network-level anti-jamming subsystem performs reasonable frequency band allocation and management for lower-level sub-users when link-level anti-jamming fails to further enhance a frequency domain anti-jamming capability of the entire system. The users make intelligent frequency usage decisions through a dynamic spectrum anti-jamming algorithm based on reinforcement learning to effectively avoid external malicious jamming, realize dynamic spectrum access, and enhance a frequency domain anti-jamming capability of the system.

Abstract: An unmanned aerial vehicle (UAV) task cooperation method based on an overlapping coalition formation (OCF) game includes: constructing a sequential OCF game model for a UAV multi-task cooperation problem; using a bilateral mutual benefit transfer (BMBT) order that is biased toward the utility of a whole coalition to evaluate a preference of a UAV for a coalitional structure; optimizing task resource allocation of the UAV under an overlapping coalitional structure by using a preference gravity-guided Tabu Search algorithm to form a stable coalitional structure; and optimizing a transmission strategy based on the current coalitional structure, an updated status of a task resource allocation scheme of the UAV, and a current fading environment, so as to maximize task execution utility of a UAV network. The method quantifies characteristics of resource properties of the UAV and a task, and optimizes the task resource allocation of the UAV under the overlapping coalitional structure.

Abstract: An unmanned aerial vehicle (UAV) task cooperation method based on an overlapping coalition formation (OCF) game includes: constructing a sequential OCF game model for a UAV multi-task cooperation problem; using a bilateral mutual benefit transfer (BMBT) order that is biased toward the utility of a whole coalition to evaluate a preference of a UAV for a coalitional structure; optimizing task resource allocation of the UAV under an overlapping coalitional structure by using a preference gravity-guided Tabu Search algorithm to form a stable coalitional structure; and optimizing a transmission strategy based on the current coalitional structure, an updated status of a task resource allocation scheme of the UAV, and a current fading environment, so as to maximize task execution utility of a UAV network. The method quantifies characteristics of resource properties of the UAV and a task, and optimizes the task resource allocation of the UAV under the overlapping coalitional structure.

Abstract: A joint link-level and network-level intelligent system and method for dynamic spectrum anti-jamming are provided. The system includes a link-level anti-jamming subsystem and a network-level anti-jamming subsystem. The link-level anti-jamming subsystem sets a reward value as system transmission throughput in a single decision cycle, and a user makes an intelligent frequency usage decision based on the obtained reward value to skip a frequency band in which jamming exists. The network-level anti-jamming subsystem performs reasonable frequency band allocation and management for lower-level sub-users when link-level anti-jamming fails to further enhance a frequency domain anti-jamming capability of the entire system. The users make intelligent frequency usage decisions through a dynamic spectrum anti-jamming algorithm based on reinforcement learning to effectively avoid external malicious jamming, realize dynamic spectrum access, and enhance a frequency domain anti-jamming capability of the system.

Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

Abstract: The present invention provides nucleic acid molecules that inhibit EGFR expression. Methods of using the nucleic acid molecules are also provided.

Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

Abstract: Compositions and methods for treating diseases, such as cancers. The compositions are effective to silence, down-regulate or suppress the expression of a validated target gene by stimulating the process of RNA interference of gene expression, thus inhibiting tumor growth. The invention also provides methods for treating diseases, such as cancers, by inactivation of a validated target gene product, using neutralizing antibody or small molecule drug, to inhibit tumor growth. More particularly, the compositions and methods are directed toward a cancer or a precancerous growth in a mammal, associated with pathological expression of a certain target genes identified herein. The compositions inhibit expression of the target gene when introduced into a tissue of the mammal. The methods include administering the compositions of the invention to a subject in need thereof in an amount effective to inhibit expression of a target gene in a cancerous tissue or organ.

Abstract: The present invention provides nucleic acid molecules that modulate the expression of molecules in the angiopoietin/Tie2 signaling pathway. Methods of using the nucleic acid molecules are also provided.

Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

Abstract: The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.

Abstract: The invention relates to nucleic acid molecule compositions for use in modulating the expression and activity of VEGF pathway genes and decreasing unwanted neovascularization, including tumor angiogenesis, by RNA interference and methods and compositions comprising the nucleic acid molecules.

Abstract: The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.

Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

Abstract: This invention describes compositions and methods using siRNA to target various genes expressed in cells of transplanted organs or tissues and/or genes expressed in the host to improve the success of the transplantation.

Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

Abstract: Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.